IMC-002
- Generic Name
- IMC-002
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
Phase 1
Not yet recruiting
- Conditions
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06557174
Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT05805943
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
Phase 1
Not yet recruiting
- Conditions
- B-cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05771883
A Study of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ImmuneOncia Therapeutics Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05276310
- Locations
- 🇰🇷
Asan Medical Center, Republic of Korea, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04746131
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath